M&A
Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals
Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty
Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A
Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.
Roche Accelerates Obesity Drug Development and Explores M&A Opportunities
Roche, obesity drugs, M&A, pharmaceuticals, drug development
AbbVie Acquires Celsius Therapeutics for $250 Million, Expanding Inflammatory Disease Portfolio
AbbVie, Celsius Therapeutics, Acquisition, Inflammatory Diseases, M&A, Biotech
Novartis Appoints Ex-Bristol Myers CEO Giovanni Caforio as Chair: Potential for Future M&A Deals?
Novartis, Bristol Myers, Giovanni Caforio, Chair, Mergers and Acquisitions (M&A), Pharmaceutical Industry, Corporate Strategy, Leadership Change.